EU-funded study investigates kidney regeneration potential

A paper published in The Lancet journal, as part of a series on renal medicine, has questioned if kidney regeneration may be possible in human beings as it is in fish and other lower vertebrates. The work is part of an ongoing EU-funded research project on the possibilities of kidney regeneration, and was carried out by a team from the Mario Negri Institute for Pharmacological Research in Bergamo, Italy.

The study is part of the 3-year, 10-partner STAR-T REK (Set up and comparison of multiple stem cell approaches for kidney repair) project, which received EUR 3 million under the Health Theme of the Seventh Framework Programme (FP7). The aim of the project is to examine how kidney regeneration could be accomplished, a treatment that is becoming imperative given the increasing rates of end-stage renal failure.

Organ regeneration occurs in both the plant and animal worlds. Fish can regenerate a kidney and the axolotl, a type of salamander found in Mexico, can regenerate an entire lost limb by converting adult tissue near the amputated area into progenitor cells which reform the limb.

Human kidneys, however, have a restricted ability to regenerate. The focus of the STAR-T REK project, therefore, is to investigate possible treatments to trigger kidney regeneration, including the use of bone marrow-derived stem cells, renal adult stem cells and foetal renal stem cells.

"Improved understanding of the mechanisms of kidney repair has stimulated researchers to clarify whether supplementary cells injected into an acutely damaged kidney might aid repair and regeneration of injured tissue, thus accelerating and augmenting the ongoing natural healing process," the authors write in the journal. "Adult stem cells, either derived from bone marrow or of renal origin, might participate in cellular repair and tissue remodelling after acute renal injury."

However, the study questions whether chronic kidney damage, which has many different causes, can be repaired. It discusses the relative merits of different drug treatments for kidney damage including the importance of using angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type I receptor blockers (ARBs) in the prevention of kidney damage.

Recent parallel research has shown that eight-year ACE inhibitor therapy stabilised kidney function in six patients with type 1 diabetes who would otherwise have progressed to end-stage kidney disease within six months. This provides evidence that ACE inhibitor therapy might be useful for kidney repair and regeneration treatment.

The authors also suggest that this therapy could be extended by using ACE 1 inhibitors at much higher doses than is usually recommended for blood pressure control with an ARB and a diuretic. This treatment has been trialled on 112 patients and resulted in only 2 out of 56 patients progressing to end-stage kidney disease compared with 17 out of 56 controls.

The authors conclude: "Studies in man will improve the understanding of the genetics governing progression and regression of chronic kidney disease and genes associated with favourable outcomes. Enhanced understanding of mechanisms of action of already available drugs with renoprotective capacity will pave the way to unravel novel pathways that are possibly relevant to renal repair.

"Together, insights from human genetics and mechanistic studies on renoprotection will contribute to the design of molecules targeted to genes relevant to the pathophysiology of regeneration, with the goal of kidney regeneration instead of dialysis or renal transplantation."

For more information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...